CtDNA KRAS Mutation Levels and Outcomes in Non-Resectable Pancreatic Cancer

CtDNA KRAS Mutation Levels and Outcomes in Non-Resectable Pancreatic Cancer

Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/